Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers

American Journal of Ophthalmology

Volumn 159, Issue 5, 2015, Pages 980-985.e1

  Levy, Brian ^a,b   Ramirez, Nancy ^a,b   Novack, Gary D ^c   Kopczynski, Casey ^a,b  

^a and Durham   (United States)

^b PharmaLogic Development Inc ^*  (United States)

^c PHARMALOGIC DEVELOPMENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AR 13324; AR 13503; DRUG METABOLITE; EYE DROPS; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; RHO KINASE;

ADULT; AGED; ARTICLE; BIOMICROSCOPY; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL LABORATORY; COLOR VISION DEFECT; CONJUNCTIVAL HYPEREMIA; CORNEAL STAINING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEART RATE; HISPANIC; HUMAN; INTRAOCULAR PRESSURE; LIMIT OF QUANTITATION; MALE; MORNING DOSAGE; OCULAR PRURITUS; OPHTHALMOSCOPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STAINING; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; NORMAL HUMAN; OCULOPLETHYSMOGRAPHY; TANDEM MASS SPECTROMETRY; TOPICAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OPHTHALMOSCOPY; RHO-ASSOCIATED KINASES; TANDEM MASS SPECTROMETRY; TONOMETRY, OCULAR; YOUNG ADULT;

EID: 84927574746     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.01.026     Document Type: Article

References (30)

1. AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol 130 4 2000 429 440
2. A. Heijl, M.C. Leske, and B. Bengtsson et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial Arch Ophthalmol 120 10 2002 1268 1279
3. M.A. Kass, D.K. Heuer, and E.J. Higginbotham et al. Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol 120 6 2002 701 713
4. P.R. Lichter, D.C. Musch, and B.W. Gillespie et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery Ophthalmology 108 11 2001 1943 1953
5. American Academy of Ophthalmology Glaucoma Panel Preferred Practice Pattern: Primary Open-Angle Glaucoma 2010 American Academy of Ophthalmology San Francisco
6. American Academy of Ophthalmology Glaucoma Panel Preferred Practice Pattern: Primary Open-Angle Glaucoma Suspect 2010 American Academy of Ophthalmology San Francisco
7. European Glaucoma Society Terminology and Guidelines for Glaucoma 2014 PubliComm Savona, Italy
8. M.V. Boland, D.S. Chang, T. Frazier, R. Plyler, and D.S. Friedman Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the Automated Dosing Reminder Study JAMA Ophthalmol 132 7 2014 838 844
9. A.L. Robin, G.D. Novack, D.W. Covert, R.S. Crockett, and T.S. Marcic Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use Am J Ophthalmol 144 3 2007 533 540
10. C.C. Kopczynski, and D.L. Epstein Emerging trabecular outflow drugs J Ocul Pharmacol Ther 30 2-3 2013 85 87
11. B. Tian, and P.L. Kaufman Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys Exp Eye Res 80 2 2005 215 225
12. H. Tokushige, M. Inatani, and S. Nemoto et al. Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys Invest Ophthalmol Vis Sci 48 7 2007 3216 3222
13. M. Honjo, M. Inatani, and N. Kido et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes Arch Ophthalmol 119 8 2001 1171 1178
14. R.D. Williams, G.D. Novack, T. van Haarlem, and C. Kopczynski AR-12286 Phase2a Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension Am J Ophthalmol 152 5 2011 834 841
15. C. Kopczynski, G.D. Novack, D. Swearingen, and T. van Haarlem Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers Br J Ophthalmol 97 5 2013 567 572
16. K. Hedman, and A. Alm A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol Eur J Ophthalmol 10 2 2000 95 104
17. A. Heijl, M.C. Leske, L. Hyman, Z. Yang, and B. Bengtsson Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial Acta Ophthalmol 89 8 2011 749 754
18. G.D. Novack, J.C. Lue, and E. Duzman Power estimates in designing glaucoma trials Glaucoma 11 6 1989 166 168
19. R.-F. Wang, J.E. Williamson, C. Kopczynski, and J.B. Serle Effect of 0.04% AR-13324, a ROCK and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes J Glaucoma 24 1 2015 51 54
20. M. Uehata, T. Ishizaki, and H. Satoh et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 6654 1997 990 994
21. J. Bacharach, H.B. Dubiner, B. Levy, C.C. Kopczynski, G.D. Novack AR-13324-CS202 Study Group Double-masked, randomized, dose-response study of AR-13324 vs. latanoprost in patients with elevated intraocular pressure Ophthalmology 122 2 2015 302 307
22. H. Tanihara, M. Inatani, M. Honjo, H. Tokushige, J. Azuma, and M. Araie Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers Arch Ophthalmol 126 3 2008 309 315
23. H. Tanihara, T. Inoue, T. Yamamoto, Y. Kuwayama, H. Abe, and M. Araie Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115 JAMA Ophthalmol 131 10 2013 1288 1295
24. W.E. Sponsel, J. Mensah, and J.W. Kiel et al. Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye Am J Ophthalmol 130 2 2000 151 159
25. C. Linden, and A. Alm Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes Acta Ophthalmol Scand 75 4 1997 412 415
26. K.S. Lim, C.B. Nau, and M.M. O'Byrne et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study Ophthalmology 115 5 2008 790 795
27. Kiel JW, Kopczynski C. Effect of AR-13324 on episcleral venous pressure (EVP) in Dutch Belted rabbits. J Ocul Pharmacol Ther. In press.
28. R.F. Brubaker Goldmann's equation and clinical measures of aqueous dynamics Exp Eye Res 78 3 2004 633 637
29. H. Goldmann Out-flow pressure, minute volume and resistance of the anterior chamber flow in man Doc Ophthalmol 5-6 1 1951 278 356
30. J.M. Selbach, K. Posielek, K.P. Steuhl, and S. Kremmer Episcleral venous pressure in untreated primary open-angle and normal-tension glaucoma Ophthalmologica 219 6 2005 357 361